Saxagliptin: are we well informed about it?

• Leonid Yu. Morgunov

Abstract

Saxagliptin is a modern strong and effective DPP-4 inhibitor which is used as a monotherapy or in double or triple combination with other oral hypoglycemic agents in the treatment of type 2 diabetes. Treatment with saxagliptin do not increase the risk of hypoglycemia and cardiovascular diseases. The results of numerous clinical studies confirmed the efficacy and safety of saxagliptin in patients of different age groups with comorbid diseases and demonstrated new opportunities in its use.

Keywords:saxagliptin, Onglyza, dipeptidyl peptidase-4 inhibitors, diabetes mellitus type 2, safety

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)